Form 4: Lilly Endowment Sells $39M in Eli Lilly Stock

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 37,148 shares of common stock for approximately $39 million through pre-arranged Rule 10b5-1 plans.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), sold a total of 37,148 shares of common stock.
• The sales occurred on November 20, 2025, at weighted average prices ranging from $1,050.364 to $1,055.391 per share.
• The total value of the shares sold is approximately $39 million.
• Following these transactions, Lilly Endowment Inc. beneficially owns 92,607,304 shares of Eli Lilly & Co. common stock.
• The transactions were executed pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The sale by a 10% owner is a significant transaction, but its execution under a Rule 10b5-1 plan mitigates negative sentiment, suggesting it's a pre-planned event rather than a reaction to new adverse information. The Endowment still holds a very large stake.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information.
• Lilly Endowment Inc. retains a substantial beneficial ownership of 92,607,304 shares, demonstrating continued significant investment in Eli Lilly & Co.

Negatives

• A significant sale of shares by a 10% owner, even if pre-planned, could be perceived negatively by some investors, potentially signaling a diversification strategy or a belief that the stock has reached a certain valuation.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent market risk associated with stock transactions.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Diane M. Stenson, Vice President and Treasurer, signed the filing on behalf of Lilly Endowment Inc.

Industry Context

This Form 4 filing reports an insider transaction by a significant institutional shareholder of Eli Lilly & Co., a major pharmaceutical company. Such transactions are common for large endowments and typically reflect portfolio rebalancing or pre-planned liquidity events rather than specific industry-related news or trends. The pharmaceutical industry continues to see significant R&D investment and M&A activity, but this filing does not directly relate to those broader trends.

Comparison to Industry Standards

• Not applicable. This filing reports an insider transaction by a 10% owner, which is a routine disclosure for beneficial ownership changes and does not provide data for comparison to industry-specific operational or financial benchmarks.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., engaged in the sale of common stock, which constitutes a related party transaction due to its significant ownership stake.

Stakeholder Impact

• Shareholders: May interpret the sale by a major institutional investor as a signal, though the 10b5-1 plan suggests it's not based on new information. The remaining large stake indicates continued confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this beneficial ownership change is expected.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Eli Lilly & Co. or Lilly Endowment Inc. beyond the reporting of these transactions.

Key Dates

Recommendation

The sale by Lilly Endowment Inc. is a substantial transaction, but its execution under a Rule 10b5-1 plan suggests it's a pre-scheduled portfolio management decision rather than a reaction to new fundamental information about Eli Lilly & Co. Given the Endowment's continued significant ownership, this transaction alone does not warrant a change in investment thesis for LLY. Investors should monitor future filings and company performance, but for now, a 'hold' recommendation is appropriate.

Keywords

Eli Lilly, LLY, Lilly Endowment, Form 4, Insider Trading, Stock Sale, Beneficial Ownership, 10b5-1 Plan, Pharmaceuticals, Biotechnology